Ovid Therapeutics (NASDAQ:OVID – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03, Zacks reports. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%.
Ovid Therapeutics Stock Down 1.8 %
OVID stock traded down $0.01 during midday trading on Tuesday, hitting $0.48. The company’s stock had a trading volume of 21,722 shares, compared to its average volume of 419,015. The firm has a 50-day simple moving average of $0.69 and a 200-day simple moving average of $0.97. The firm has a market capitalization of $34.16 million, a P/E ratio of -1.03 and a beta of 0.29. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18. Ovid Therapeutics has a 52-week low of $0.47 and a 52-week high of $3.45.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Ovid Therapeutics stock. Bank of America Corp DE raised its stake in Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) by 49.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,733 shares of the company’s stock after purchasing an additional 18,841 shares during the period. Bank of America Corp DE owned 0.08% of Ovid Therapeutics worth $53,000 as of its most recent SEC filing. 72.24% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
View Our Latest Stock Analysis on Ovid Therapeutics
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
Read More
- Five stocks we like better than Ovid Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla Stock is Oversold – Is Now the Time to Be Brave?
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Stocks Institutions Are Quietly Dumping
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.